Stem Cells vs Knee Replacement: What Does the Evidence Actually Show?

If an orthopaedic surgeon has told you that your knee is "bone on bone" and that a replacement is the next step, you are in a large group. You are also, probably, in the group that has spent the evenings since then reading about stem cell injections — and finding two kinds of content: clinics describing them as a way to "avoid surgery," and forums describing them as expensive placebo.

Neither is an honest summary of the evidence. This article sets out what the published trials show for knee replacement and for intra-articular stem cell therapy, what each one reliably does and does not do, where the research is genuinely thin, and the situations where a replacement is clearly the correct answer and an injection is not.

The quick answer

Total knee replacement is one of the most studied operations in medicine. In a randomized trial it produced substantially greater improvement in pain and function at twelve months than non-surgical care alone, at the cost of more serious adverse events.[1] Most implants last 25 years or more.[2] And yet roughly one in five patients report being dissatisfied with the result.[3]

Intra-articular mesenchymal stem cell (MSC) therapy for knee osteoarthritis has multiple completed randomized controlled trials, several reporting improvement in pain and function that held up over one to four years, alongside meta-analyses that rate the overall certainty of that evidence as low to moderate. It is a day procedure with a good safety record, it does not remove the option of a replacement later, and it does not rebuild a joint that has structurally collapsed.

The short version: replacement is the more proven treatment for advanced disease, and it is irreversible. Cell therapy is the less proven treatment for moderate disease, and it is not. Which of those trade-offs is right depends almost entirely on how far your knee has progressed.

What each option actually is

Total knee replacement (arthroplasty) removes the worn cartilage and bone surfaces of the femur and tibia and replaces them with metal and polyethylene components. It is a mechanical substitution, not a repair. The joint you had is gone; the new one is engineered.

Partial (unicompartmental) replacement resurfaces only one compartment of the knee — usually the inner side — when the damage is confined there. Faster recovery, but higher revision rates over the long run.[2]

Intra-articular MSC therapy injects mesenchymal stromal cells into the joint space, typically under ultrasound or fluoroscopic guidance. Cells may come from the patient's own bone marrow or fat, or from a donor source such as umbilical cord tissue. The mechanism is thought to be predominantly biological signalling — the cells release anti-inflammatory and trophic factors that change the joint's environment — rather than cells physically growing into new cartilage. That distinction matters, because "regrowing your cartilage" is a claim you will encounter in marketing, and it overstates what has been demonstrated in humans.

What the knee replacement evidence shows

The reference trial is the Danish study by Skou and colleagues, published in the New England Journal of Medicine in 2015. Patients with moderate-to-severe knee osteoarthritis who were eligible for replacement were randomized to replacement followed by a structured non-surgical programme, or the non-surgical programme alone. At twelve months, the replacement group had significantly greater improvement in pain, function, and quality of life — but also more serious adverse events, including deep vein thrombosis and stiffness requiring manipulation. Notably, the non-surgical group improved meaningfully too, and only a minority of them chose to cross over to surgery within the year.[1]

On durability, the 2019 Lancet systematic review by Evans and colleagues pooled case series and national registry data with more than fifteen years of follow-up. It estimated that around 82% of total knee replacements were still in place at 25 years, and around 70% of partial replacements.[2] That is a strong result and it is why replacement remains the definitive treatment for end-stage disease.

The caveat is satisfaction. Bourne and colleagues, analysing a large cohort in Clinical Orthopaedics and Related Research, found that roughly one in five patients were not satisfied with their knee replacement, with unmet expectations and persisting pain the strongest predictors.[3] A replacement is not a guarantee of a pain-free knee. It is a highly reliable operation with a meaningful minority of disappointing outcomes — and once done, there is no returning to the original joint.

What the stem cell evidence shows

Unlike much of the regenerative field, knee osteoarthritis does have randomized controlled trials rather than only case series — and the number has grown quickly.

Lamo-Espinosa and colleagues randomized patients with knee osteoarthritis to one of two doses of autologous bone marrow MSCs or hyaluronic acid alone. Their long-term follow-up, published in the Journal of Translational Medicine in 2018, reported that improvements in pain and function in the cell-treated groups were maintained at four years, with the higher dose performing better.[4] The trial was small, which limits how far it generalizes.

Matas and colleagues, publishing in Stem Cells Translational Medicine in 2019, ran a randomized phase I/II trial of umbilical cord-derived MSCs against hyaluronic acid. A repeated-dose regimen — two injections six months apart — produced greater improvement in pain and function at twelve months than either a single dose or hyaluronic acid.[5] This is one of the more informative trials in the field because it addressed dosing, not just whether cells beat a comparator.

Pulling the trial data together, a 2024 systematic review and meta-analysis of randomized trials in Osteoarthritis and Cartilage by Sadeghirad and colleagues found that MSC therapy was associated with improvements in pain and function compared with control treatments — but rated the certainty of that evidence as low to moderate, citing small samples and inconsistency between trials.[6] A 2025 meta-analysis in Stem Cell Research & Therapy reached a broadly similar conclusion: a favourable safety profile and signals of benefit in pain and function, with substantial heterogeneity in cell source, dose, and outcome measures across the included trials.[7]

The consistent picture across this literature is that cell therapy is safe, that it appears to help a meaningful share of patients with moderate disease, and that the evidence base is not yet large or uniform enough for anyone to promise you a result.

Where the research is genuinely weak

An honest reading has to name the limitations, because they are substantial:

• No head-to-head trials. Replacement and cell therapy have never been randomized against each other in the same population. Every comparison is indirect.
• Small samples. Most MSC trials enrol tens to low hundreds of patients, against surgical datasets covering hundreds of thousands.
• Heterogeneity. Bone marrow, adipose, and umbilical cord cells are not interchangeable, doses vary by an order of magnitude, and outcome measures differ. Pooled results should be read with that in mind.
• Short follow-up. Four years is about the longest robust follow-up for cells. Replacement outcomes are tracked over decades.
• Placebo response. Knee pain responds strongly to the act of being treated. Trials without a sham or active comparator overstate benefit.
• Structural change is unproven. Some trials report imaging changes; none has shown that cells reliably regrow cartilage in a way that alters the long-term course of the disease.

Any clinic presenting this evidence base as settled is misrepresenting it. Our broader assessment of where the field stands is in the guide to what MSC research actually shows in 2026.

Who may be a candidate for cell therapy

Based on the inclusion criteria used across the published trials, the patients most plausibly suited to intra-articular MSC therapy tend to share these features:

• Symptomatic knee osteoarthritis, generally Kellgren-Lawrence grade 2 or 3 on X-ray
• Cartilage still present on imaging — thinning, not absent
• Failure of a genuine course of conservative care: exercise therapy, weight management, medication, and often hyaluronic acid or PRP
• Reasonable joint alignment, without severe deformity
• Pain that limits activity but has not yet reached the point where a surgeon would recommend replacement
• An understanding that the goal is symptom improvement and possibly delay, not a rebuilt knee, and that non-response is possible

The last point is the one we spend the most time on. For a patient in their fifties with moderate disease, the realistic aim of cell therapy is to reduce pain, improve function, and potentially push a replacement further into the future — which has real value, because implants placed later are less likely to need revision within the patient's lifetime. That is a different promise from "avoiding surgery," and we would rather you hear the difference from us.

When replacement is clearly the right answer

Cell therapy may not be right for you, and there are situations where it is clearly not:

• End-stage, bone-on-bone disease. Kellgren-Lawrence grade 4 with no measurable joint space. There is little cartilage left for a biological therapy to influence. This is a structural problem and it wants a structural solution.
• Severe malalignment or instability. A markedly bowed or knock-kneed joint, or one that gives way, is not corrected by an injection.
• Large areas of exposed bone with cysts and deformity on imaging.
• Pain that is constant, at rest and at night, and no longer responds to anything. This is the profile in which replacement produces its most dramatic improvements.
• Active infection, active malignancy, or pregnancy.
• Inflammatory arthritis — rheumatoid, psoriatic — driving the joint damage, which needs its own treatment first.

We decline patients on these grounds regularly, and would rather say so before you book travel. Our page on orthopaedic and joint conditions explains how we assess cases across the knee, hip, shoulder and spine, and our earlier post on stem cell therapy for knee osteoarthritis covers what treatment involves in detail. What a course of treatment costs in Colombia relative to the United States is set out in our cost comparison guide.

How to think about the decision

A few principles hold whichever way you go:

Sequence matters. Cell therapy does not close the door on a replacement. A replacement closes the door on everything else. Where both are reasonable and there is no urgency, trying the less irreversible option first is a defensible order of operations — a judgement to make with your own orthopaedic surgeon, not a rule.

Match the treatment to the stage. Biological therapies are aimed at a joint that is degenerating but still structurally present. Replacement is aimed at a joint that is no longer functioning as one. Most disappointment in this field comes from applying one to the other.

Timing a replacement is itself a decision. Implants have a finite lifespan. A replacement at 52 is meaningfully more likely to need revision surgery than one at 65, and revisions are harder operations with worse outcomes. Anything that safely delays the first replacement — including exercise therapy, weight loss, and possibly cell therapy — has value beyond the symptom relief it provides.

Get your imaging read by someone with nothing to sell you. An X-ray showing arthritis does not, on its own, tell you which treatment you need. Grade, alignment, and the match between your symptoms and your imaging do.

Ask about non-response rates. Every genuine treatment has one. A clinic unwilling to tell you what proportion of its patients get no meaningful benefit is not giving you informed consent. The questions worth asking are set out in our guide to choosing a stem cell clinic.

The bottom line

Knee replacement has stronger and longer evidence, and for end-stage disease it is usually the right answer. It is also irreversible, carries surgical risk, and leaves around one in five patients dissatisfied. Intra-articular stem cell therapy has a real but immature body of randomized evidence showing a good safety profile and improvements in pain and function in a subset of patients with moderate disease — and no evidence at all that it can substitute for a replacement once the joint has structurally failed.

What no one can honestly tell you today is which will work better for you specifically, because that trial has not been run. What we can do is look at your X-rays or MRI and your history and tell you which category you fall into — including when the answer is that you need an orthopaedic surgeon rather than us.